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The Primodos components 
Norethisterone acetate and Ethinyl 
estradiol induce developmental 
abnormalities in zebrafish embryos
Samantha Brown1, Lucas Rosa Fraga1,3, Gary Cameron2, Lynda Erskine1 & Neil Vargesson  1
Primodos was a hormone pregnancy test used between 1958–1978 that has been implicated with 
causing a range of birth defects ever since. Though Primodos is no longer used, it’s components, 
Norethisterone acetate and Ethinyl estradiol, are used in other medications today including treatments 
for endometriosis and contraceptives. However, whether Primodos caused birth defects or not remains 
controversial, and has been little investigated. Here we used the developing zebrafish embryo, a 
human cell-line and mouse retinal explants to investigate the actions of the components of Primodos 
upon embryonic and tissue development. We show that Norethisterone acetate and Ethinyl estradiol 
cause embryonic damage in a dose and time responsive manner. The damage occurs rapidly after drug 
exposure, affecting multiple organ systems. Moreover, we found that the Norethisterone acetate 
and Ethinyl estradiol mixture can affect nerve outgrowth and blood vessel patterning directly and 
accumulates in the forming embryo for at least 24 hrs. These data demonstrate that Norethisterone 
acetate and Ethinyl estradiol are potentially teratogenic, depending on dose and embryonic stage of 
development in the zebrafish. Further work in mammalian model species are now required to build on 
these findings and determine if placental embryos also are affected by synthetic sex hormones and their 
mechanisms of action.
Primodos (known as Duogynon in Germany) is a trade name of a hormonal-based pregnancy test composed of 
10 mg of norethisterone acetate (NA), a synthetic progestogen, and 0.02 mg of ethinyl estradiol (EE), a synthetic 
oestrogen. Primodos was marketed in the UK between 1958 and 1978 as a method of testing for pregnancy, based 
on whether the woman menstruated after taking Primodos or not1–3. Its mechanism of action was simple. It 
causes a rapid spike in the levels of progesterone. If a woman is pregnant she will have higher levels of progester-
one, which maintain pregnancy normally. It was presumed that the increase in progesterone would be balanced 
out by the normally higher levels of pregnancy induced progesterone. If she was not pregnant, then the rapid 
spike in progesterone would be lost, and this mimics the end of the menstrual cycle, resulting in a small bleed. 
Intake of Primodos during pregnancy has been potentially linked to a range of birth defects including neural 
tube closure defects, cleft lip and palate, limb defects and cardiovascular defects2,4–10. Several epidemiological 
studies have provided support for a potential link between Primodos, as well as other hormone pregnancy tests, 
and birth defects2,7,8,11–14. Further support for the idea that Primodos is teratogenic has come from experiments 
in animal models, demonstrating that progestins and synthetic oestrogens induce brain malformations, embry-
onic death and genital malformation in mice foetuses15–17, rats18 and embryonic death and abortion in rhesus 
monkey, Cynomolgus monkey and baboons17,19. However, other epidemiological studies have failed to find a link 
between the use of hormone pregnancy test, such as Primodos, and causation of birth defects9,20. In addition, 
some experimental studies found no congenital abnormalities in rats and rabbits exposed to progestin’s and syn-
thetic oestrogens17,21,22. Moreover, studies looking at external genitalia malformations caused by exposure to sex 
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hormones in the first trimester suggest there was no causal association23. Based on the current evidence it is far 
from clear whether exposure to Primodos or its components has the potential to cause embryonic or foetal dam-
age. Primodos is no longer on the market but its components, alone or in combination, are still found in many 
medications today. Examples of their use today include hormone replacement therapy, secondary amenorrhea 
and period delay as well as emergency contraception (ie: morning after pill) and in some contraceptive prepara-
tions but at much smaller dosages than Primodos was used at (less than 0.5 mg)17,24–28. Today the packaging of 
drugs containing these components carries warning signs they should not be used in pregnancy as there is a risk 
to the unborn child27,28. However, whether these drugs are teratogenic remains unclear.
The zebrafish embryo has become increasingly popular in drug screening assays due to its rapid develop-
ment, optical transparency and the ability to visualise and follow development live and in vivo29. Indeed, many 
drugs have actions in zebrafish embryos that are similar to actions in mammalian species including humans. For 
example, thalidomide exposure causes damage in zebrafish embryos in similar or equivalent tissues damaged in 
humans following thalidomide exposure30–33. Furthermore, zebrafish embryos are becoming increasingly popular 
to screen compounds to identify lead compounds that could be used for further analysis in mammalian species 
and/or to determine if compounds may have harmful effects29,30,34–37.
Using a combination of in vivo and in vitro assays for teratogenesis, angiogenesis, cell death, cell proliferation 
and neurotoxicity the effects of Norethisterone acetate and Ethinyl estradiol (in a ratio similar to that seen in 
Primodos) was analysed in zebrafish embryos, mouse retinal explants and HUVEC cell culture. We found that 
these compounds had a dose and time dependent effect on zebrafish embryo development, affecting eyes, fins, 
the spine, overall length of the embryo, vascular development and nerve growth and defasciculation. Moreover, 
our results demonstrate that the effect of these compounds depends on the developmental stage of the embryos. 
Its actions on the embryo are rapid and that the amount of drug that enters the embryo accumulates for 24 hr. Our 
results indicate that direct exposure to a high dose of a mixture of Norethisterone acetate and Ethinyl estradiol 
induces morphological defects in developing zebrafish embryos.
Results
A Norethisterone acetate (NA) and Ethinyl estradiol (EE) mixture impairs zebrafish develop-
ment and survival in a dose responsive manner. Primodos, which is no longer made, was composed of 
10 mg Norethisterone acetate (NA) and 0.02 mg Ethinyl estradiol (EE). We therefore screened the effect on zebraf-
ish embryos of a NA/EE-mixture at a ratio of 500:1 (NA:EE; equivalent ratio of their formulation in Primodos) 
at a range of concentrations. In the majority of experiments, drugs were added at 24 hpf, and the embryos fixed 6 
to 72 hrs later (n ≥ 15 per treatment; Fig. 1A,B). This developmental time point is the period where most tissues 
and organs are rapidly developing and has been used in previous work in the lab analysing drug actions upon 
embryogenesis30,32,34,35,37–39. Moreover, this time period relates to approximately weeks 6–10 in human embryo 
development when hormonal pregnancy tests were likely to be used.
Lower doses of the NA/EE-mixture, 1.5 µg/mL NA + 3.125 ng/mL EE and 3.125 µg/mL NA + 6.25 ng/mL EE 
were non-lethal (n = 15), and had no obvious effect on embryonic development (Fig. 1A,B). However, as the 
dose increased we saw malformations in a dose-dependent manner and higher doses were 100% embryolethal. 
We observed some embryonic defects (approx. 20%) and a small increase in embryonic death (approx. 10%) at 
6.25 µg/mL NA + 12.5 ng/mL EE (n = 62). At 12.5 µg/mL NA + 25 ng/mL EE (n = 91) markedly more embryos 
displayed damage (approx. 92% of all embryos had damage) and almost 50% of the embryos died (Fig. 1A,B). 
Doses of 25 µg/mL NA + 50 ng/mL EE or higher caused 100% lethality (n = 23) (Fig. 1A,B).
To further analyse the dose-dependent effect of NA/EE-mixture upon embryogenesis, we measured the over-
all size of the embryos, pectoral fin, otic vesicle and eye size of drug treated embryos and compared to DMSO 
controls. Lower doses of 1.5 µg/mL NA + 3.125ng/mL EE and 3.125 µg/ml + NA/6.25 ng/ml EE had no significant 
effect on the size of any of these structures. However, in embryos exposed to NA 6.25 μg/mL NA and 12.5 ng/mL 
EE the length of the pectoral fins and overall body length were decreased significantly (Fig. 1C–G). At a concen-
tration of 12.5 μg/mL NA + 25 ng/mL EE the eye and otic vesicle were also decreased significantly in size. At this 
concentration, the embryos also exhibited a range of other malformations including bent spine, smaller overall 
size, pericardial and yolk sac oedema and oedematous yolk sac extension (Fig. 1E,G). Measurement of embryo 
length, pectoral fin size, otic vesicle size and eye diameter demonstrated 15–17% reduction in size of these param-
eters compared to the DMSO controls (Fig. 1C–C”, E–E” and G). This data demonstrates that the NA/EE-mixture 
impairs embryonic development in a dose dependent manner.
Embryos at earlier developmental stages are more sensitive to the NA/EE-mixture. When 
applied at 24 hpf the 12.5 μg/mL NA + 25 ng/mL EE mixture gave a 57% survival rate with the majority (92%) of 
embryos presenting defects (Fig. 1). We therefore focused our further experiments on this dose. First, we asked 
if this drug combination had a differential effect on embryos at different stages of development. We exposed 
6 hpf, 24 hpf, 48 hpf and 72 hpf embryos to 12.5 μg/mL NA + 25 ng/mL EE and analysed the embryos 24 hrs later 
(Fig. 2). We found that early embryos are more severely affected than later stage (older) embryos (Fig. 2). Thus, 
embryos exposed at 6 hpf exhibited severely malformed tails and bent spines, malformed pericardial sacs, yolk 
sac damage/oedema and very small eyes, whereas embryos exposed at 48 hpf and at 72 hpf, had less severely 
bent spines, mild pericardial defects and their eyes and otic vesicle appeared to be normal; the only consistently 
observable issue was an oedematous yolk sac. This indicates that early stage embryos are more sensitive to the 
NA/EE-mixture than later stage embryos.
Exposure to the NA/EE-mixture causes rapid morphological damage. Next, we determined how 
quickly the NA/EE-mixture induces embryonic damage. We exposed 24 hpf embryos for differing time periods 
to the drug from 1 hr to 24 hrs (Fig. 3A–F). We found that the drug mixture acts rapidly and that the first distinct 
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Figure 1. Effects of exposure to the NA/EE Mixture upon Survival and Development of Zebrafish Embryos 
Are Time and Dose Sensitive Zebrafish embryos at 24 hpf were treated with either DMSO, NA 6.25 μg/
mL + EE 12.5 ng/mL or NA 12.5 μg/mL + EE 25 ng/mL, incubated until 96 hpf and overall body size, PF, OV 
and eye size measured. (A) The survival rate decreases as the dose increases. Survival rate starts to decrease at a 
concentration of NA 6.25 µg/mL + EE 12.5 ng/mL. (B) The rate of gross defects occurrence increases as the dose 
increases. Embryos start to present defects at a concentration of NA 6.25 µg/mL + EE 12.5 ng/mL (C–G) NA and 
EE mixture causes reduction of body size, PF, OV and eye size in a dose-dependent manner. Damage caused by 
the drugs is less severe in embryos treated with lower dose (D–D”) when compared to DMSO controls (C–C” 
and F). NA: Norethisterone acetate. EE: Ethinyl Estradiol. H: heart; YS: yolk sac; OV: otic vesicle; PF: pectoral 
fin. Black arrowhead indicates yolk sac and extension oedema. Black arrow indicates otic vesicle is smaller. 
Black asterisk denotes bent spine. White asterisk denotes reduced (D”) or missing pectoral fin (E”). White 
arrow indicates pericardial oedema. Vertical black line compares the eye diameter between NA/EE-mixture and 
DMSO treated embryos in C’, D’ and E’, and indicates diameter of the eye is altered in NA/EE-treated embryos. 
Relative length: compared to WT. Statistical significance was analysed using Student t-test. Graphs represent 
mean ± SEM. **p < 0.01, ***p < 0.001 and ****p < 0.0001. Scale bars: 250 µm.
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morphological damage was evident from 4 hrs after NA/EE-mixture application (Fig. 3G,I). We found eye size 
and body length were significantly reduced by 4 hrs of incubation. The forming heart also showed changes by 4 hrs 
of incubation in a subset of embryos (n = 2/5; Fig. 3F). Other tissues, such as the yolk sac, appeared unaffected at 
this timepoint (Fig. 3I). We also noted that movement of the embryos was inhibited after just 1 hr exposure to the 
drug mixture (Fig. 3J–N). We filmed embryos over a 2 minute period and counted the number of tail movements. 
Treated embryos made no tail movements (Fig. 3N) and were in the same position at the end of filming as at the 
start of the filming (Fig. 3K,M). In contrast control embryos were constantly moving and were in very different 
positions in the well by the end of filming (Fig. 3J,L,N). This inhibition of movement was also observed at all time-
points assessed up to and including 4 hrs of exposure (n ≥ 5). This indicates that the NA/EE-mixture acts rapidly 
upon the embryo, with some tissues more susceptible than others, and demonstrates that short-term exposure to 
the NA/EE-mixture in zebrafish induces significant defects in embryonic development and movement (n ≥ 4 for 
DMSO controls; n ≥ 5 for NA/EE-mixture).
Quantification of the dose of the drug that reaches the embryo. Next, we used LC-MS/MS Mass 
Spectroscopy to determine the concentration of the drug in the embryo. For this analysis we focused upon NA 
as levels of EE were consistently below detection rates. Embryos at 24 hpf were placed in the NA/EE-mixture 
(12.5 μg/mL NA + 25 ng/mL EE), or in DMSO or in water (untreated) for 6 hr, 24 hr or 48 hr. Embryos were 
rinsed in water and then frozen before LC-MS/MS Mass Spectroscopy analysis. We found that the level of NA in 
the embryos was 1 µg/embryo within 6 hr of treatment, peaking at 1.8 µg/embryo at 24 hr and subsiding to 1.2 µg/
embryo at 48 hr (Fig. 4). This data indicates that NA can accumulate in embryonic tissue for at least 24 hrs.
NA/EE-mixture exposure increases cell death and reduces cell proliferation throughout the 
embryo. We next investigated if cell death was induced by the NA/EE-mixture in treated embryos to poten-
tially explain the damage and phenotypes observed. In order to analyse cell death, we performed a TUNEL assay 
in embryos treated with NA/EE-mixture (12.5 μg/mL NA + 25 ng/mL EE), or DMSO and fixed at 6 hrs and 24 hrs 
after exposure (n ≥ 5 for each condition and time-point). At both time points cell death was increased signifi-
cantly in embryos treated with the NA/EE-mixture (p < 0.01; Fig. 5A–E). The increased cell death was not local-
ised to specific tissues, for example, just to the eye, pectoral fin or tail but was observed throughout the embryo, 
correlating with the decrease in overall body size as well as fin and eye size in the treated embryos.
Figure 2. The NA/EE-mixture induces morphological damage in zebrafish embryos at 6 hpf, 24 hpf, 48 hpf 
and 72 hpf in a stage-sensitive manner. Embryos at 6 hpf, 24 hpf, 48 hpf and 72 hpf were treated with either 
DMSO or NA/EE-mixture (NA 12.5 μg/mL + EE 25 ng/mL), incubated for 24 hours then fixed and imaged. 
(A–H) Embryos at 6 hpf (A,B), 24 hpf (C,D), 48 hpf (E, F), 72 hpf (G,H) treated with DMSO (A,C,E,G) or NA/
EE-mixture (B,D,F,H; n > 15 for all time points and conditions). Note: twisted spine (grey arrowhead); smaller 
eye (white asterisk); yolk sac anomalies/oedema (grey arrow), bent spine (black asterisk) and pericardial defect 
(black arrowhead). Scale bars: 250 µm.
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We also investigated if cell proliferation changes occurred in embryos treated with NA/EE-mixture. We 
treated embryos at 24 hpf, and fixed and stained for Phospho-histone H3, a marker of mitosis, at 6 hr and 24 hr 
after exposure (n = 11 for 6 hr, n = 16 for 24 hr) and compared to DMSO controls (n = 13 for 6 hr, n = 17 for 
24 hr). To ensure the consistency of the analyses, Phospho-histone H3 positive cells were counted from the posi-
tion of the yolk sac to the tail, excluding yolk sac and yolk extension. We found a decrease in the number of 
mitotic cells at both 6 hr and 24 hr in embryos exposed to the NA/EE-mixture exposed embryos compared to 
Figure 3. 3 Embryonic damage is seen within 4 hrs of NA/EE-mixture exposure and embryonic movement 
is stunted from 1 hr of exposure. Zebrafish embryos at 24 hpf were treated with either DMSO (A,C,E) or NA/
EE-mixture (B,D,F) for 1 hr (A,B), 2 hr (C,D) or 4 hr (E,F) before fixation. Overall body length, eye area and 
yolk sac area were measured. Embryos begin to show heart defects (n = 2/5) (black asterisk) and smaller body 
length (G) and eye area and pigment (H) (grey asterisk) by 4 hr exposure. At 4 hr, there is no change in the area 
of the yolk sac between DMSO control and NA/EE-mixture treated embryos (I). At 1 hr exposure, it was noted 
that there was a drastic decrease in movement in NA/EE-mixture treated embryos. This was determined using 
time lapse recording of embryos for 2 minutes and counting the number of times each embryo moved. The 
lack of movement can be visualised by comparing the starting and finishing positions of the embryos (J–M). 
In the DMSO treated well, there has been clear movement between 0 min (J) and 2 min (L), with one embryo 
having moved out of frame. Black arrows denote embryos in different positions. In comparison, the NA/
EE-mixture treated embryos can be observed to have remained in the same position between 0 min (K) and 
2 min (M). Black arrowheads show embryos in same position. The average number of movements recorded for 
DMSO treated embryos was 16 per minute compared to the average 0 per minute in the NA/EE-mixture treated 
embryos (N).
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controls (p < 0.01 at 6 h; p < 0.0001 at 24 hr; Fig. 5F–J). Similarly, to the cell death analyses we didn’t observe any 
regional variations in cell proliferation, but a general decrease in cell proliferation throughout the embryo in NA/
EE-treated embryos.
NA/EE-mixture exposure alters embryonic blood vessel patterning. Previously we have shown 
that drugs such as thalidomide and some of its analogs35,37–39 as well as antiangiogenic agents such as Sunitinib29,34 
cause damage to a range of tissues including the fins, otic vesicle and eyes through disrupting blood vessel forma-
tion. To investigate if blood vessel loss or patterning defects occur in zebrafish embryos following NA/EE-mixture 
exposure we used the transgenic fli1:EGFP reporter line of zebrafish embryos40. These embryos express enhanced 
Green Fluorescent Protein (EGFP) in blood vessels, which can be visualised live and in vivo when placed under a 
fluorescence light source30,38,40. fli1:EGFP zebrafish embryos at 24 hpf were incubated with either DMSO (n = 18 
for 6 hr, n = 21 for 24 hr) or the NA/EE-mixture (12.5 μg/mL NA + 25 ng/mL EE) and their intersomitic vessels 
(ISV) imaged at 6 and 24 hours after exposure (Fig. 6A; n = 19 for 6 hr, n = 18 for 24 hr). ISVs are easy to visualise 
at the stages assessed and, because they develop in a rostral-caudal gradient along the embryo, this enables the 
effects of compounds on formed vessels, vessels beginning to form and areas where angiogenesis is yet to be ini-
tiated, to be determined in the same embryo (Fig. 6).
Embryos incubated with DMSO (Fig. 6C,D) displayed complete dorsal vessel anastomosis 24 hours after expo-
sure (48 hpf), comparable to untreated wild-type embryos40. In contrast, incubation with the NA/EE-mixture 
(Fig. 6E,F) caused some mispatterning of vessels within 6 hr exposure (Fig. 6E) and misplacing, mispatterning 
and stunting of intersomitic vessel outgrowth throughout the spine of the embryo 24 hr following drug exposure 
(Fig. 6F). Quantification of intersomitic vessel outgrowth demonstrated no outgrowth deficit at 6 hr but signifi-
cant reduction in outgrowth by 24 hr (Fig. 6B).
Because the intersomitic vessel defects could be secondary, for example due to changes in somite formation 
which have been shown to be the cause of vessel positioning changes in Notch signalling pathway mutants41 we 
Figure 4. The concentration of NA within the developing zebrafish embryo exposed to NA/EE-mixture peaks 
at 1.8 µg/embryo at 24 hours incubation. (A) Graph depicting the concentration of NA in Untreated (water 
only) and DMSO controls compared to the concentration of NA found in zebrafish embryos exposed to NA/
EE-mixture for 6 hr, 24 hr and 48 hr. (B) Table showing average concentration of NA (±SEM) at each timepoint 
in Untreated and DMSO controls alongside NA/EE-mixture exposed embryos. This data was used to present the 
graph in (A). At all timepoints there was 0 ng/mL (±0 ng/mL) NA in both the untreated and DMSO controls. At 
6 h exposure, there was an average of 1077 ng/mL (±19.05 ng/mL) NA, peaking at 1872 ng/mL (±71.65 ng/mL) 
NA at 24 hr exposure. By 48 hr the NA concentration had started to decrease to 1164 ng/mL (±22.57 ng/mL). n 
numbers are stated in the boxed areas within the graph (A) or as (n = x) in the table (B). Statistical significance 
was analysed using Kruskal-Wallis and Dunns post hoc test. Graph and table represent mean concentration of 
NA per embryo ± SEM. **p < 0.01; ***p < 0.001.
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next studied the effect of NA/EE-mixture exposure directly using in vitro cultures of cells from a human umbilical 
vein endothelial cell line (HUVEC). HUVEC cells form networks of endothelial cell tubes which branch and pro-
vide a method to ascertain the effects of direct application of compounds to blood vessels32,38. Application of the 
NA/EE-mixture to newly plated HUVEC cells before the HUVEC cells have formed endothelial cell tubes caused 
changes to the number of branches of endothelial tubes in a dose-sensitive manner (Fig. 6G–I). Cell proliferation 
and cell number also was decreased in a concentration dependent manner (Fig. 6J,K). Despite the number of 
endothelial cells and their proliferation rates being reduced at each concentration, they were still able to form 
patterned, branched, vascular networks, though bigger gaps are seen between the endothelial tubes. This suggests 
vessels can form in the presence of the NA/EE-mixture but endothelial cell proliferation and vessel branching is 
perturbed.
NA/EE-mixture exposure affects nerve patterning and outgrowth in vivo and in vitro. We have 
demonstrated that the NA/EE-mixture treated embryos exhibited movement loss within 1 hr of exposure (Fig. 3). 
In addition, embryos also exhibit bent spines, following 24 hrs exposure. We therefore investigated the effect of the 
NA/EE-mixture upon the nervous system. First, we focused on neurite outgrowth in embryos treated with the NA/
EE-mixture. Embryos at 24 hpf treated with either DMSO or the NA/EE-mixture (12.5 μg/mL NA + 25 ng/mL EE) 
were fixed at 6 hr and 24 hr then stained with an anti-neurofilament antibody to analyse nerve patterning.
Embryos treated with NA/EE-mixture (n = 9 for 6 hr and n = 16 for 24 hr; Fig. 7B,D) presented defascicu-
lation of axons in the developing spinal cord and shortening of axonal outgrowth. In DMSO treated embryos 
axons can be seen extending through the spinal cord to midway through the spine after 6 hrs and throughout the 
spine by 24 hr exposure (Fig. 7A,C). In contrast in the NA/EE-mixture treated embryos axons had not extended 
to the midpoint of the spine by 6 hrs and failed to innervate the tail region of the embryo by 24 hr (Fig. 7B,D). 
Quantification of nerve length relative to overall body length indicated significant nerve length reduction from 
6 hrs following drug exposure (Fig. 7K). In the developing head of the embryo nerves are also disorganised, mis-
patterned and defasiculated when compared to embryos treated with DMSO (Fig. 7E,F)(n = 7 for 6 hr and n = 12 
for 24 hr). Total nerve outgrowth in the head also was reduced significantly in treated embryos (Fig. 7L).
To confirm whether the neuroinhibitory action observed in the embryos was direct we tested the effects of the NA/
EE-mixture exposure on neurite outgrowth directly using an in vitro mouse retinal explant assay32,42–44. Retinas were 
dissected from E14.5 C57BL/6 J WT mice and cultured in DMSO or in a range of concentrations of the NA/EE-mixture 
(3.125 μg/mL NA + 6.25 ng/mL EE; 6.25 μg/mL NA + 12.5 ng/mL EE; and 12.5 μg/mL NA + 25 ng/mL EE; Fig. 7G–J). 
Figure 5. Cell Death is increased and Cell Proliferation decreased in Zebrafish Embryos Treated with NA/
EE-mixture Zebrafish embryos at 24 hpf were treated with either DMSO or NA/EE-mixture and fixed at 6 hrs 
or 24 hrs post-treatment. Cell death and cell proliferation analyses were assessed by TUNEL assay (A–D) 
or antibody staining with anti-Phosphohistone H3 (F–I), respectively. The number of apoptotic cells or cell 
undergoing mitosis were counted and compared between drug treated and DMSO controls. Proliferating cells 
were counted from the position of the yolk sac to the tail, not including the yolk sac or yolk extension. (A–E) 
Embryos treated with NA/EE-mixture present a higher number of apoptotic cells at 6 hours (A,B and E) and 
24 hours (C–E). Apoptotic cells do not occur in specific regions of the embryos. White arrowheads denote 
examples of apoptotic cells, which outnumber those (if any) seen in DMSO controls. (F–J) Embryos treated 
with NA/EE-mixture present a significantly lower number of proliferating cells at 6 hours (F,G and J) and 
24 hours (H–J). Proliferating cells are reduced in all regions of the embryos. White arrows indicate regions of 
proliferating cells, markedly reduced in treated embryos. Statistical significance was analysed using unpaired t 
test. Graphs represent mean ± SEM. **p < 0.01, ****p < 0.0001. Scale bars: 250 µm.
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After 48 hr, the cultures were fixed and stained with a neuron-specific anti–β-tubulin antibody and the area of neurite 
outgrowth from the cultures quantified.
We found that the drug has a dose-dependent inhibitory effect on neurite outgrowth. Treatment with 3.125 μg/mL 
NA + 6.25 ng/mL EE had no significant effect on neurite outgrowth (n = 14; Fig. 7H,M) when compared to 
DMSO (vehicle) controls (n = 15; Fig. 7G,M). However, the extent of neurite outgrowth from retinal explants 
exposed to 6.25 μg/mL NA + 12.5 ng/mL EE (n = 13; Fig. 7I,M) and 12.5 μg/mL NA + 25 ng/mL EE (n = 13; 
Fig. 7J,M) was decreased significantly compared to DMSO controls. These findings demonstrate that the NA/
EE-mixture can inhibit nerve outgrowth when directly applied to in vitro nerve explants and can also cause 
axonal outgrowth defects in vivo.
Discussion
We have demonstrated that a mixture of NA/EE (the components of Primodos), can cause developmental anom-
alies when directly applied to zebrafish embryos. The compound acts in both a dose-dependent and time sensitive 
manner, with early exposure causing more damage than later exposure. Damage also is extremely rapid. Within 
1 hr of drug exposure at 24 hpf, embryos displayed significantly reduced movement, and, within 4 hrs of exposure, 
obvious morphological defects. Using in vitro assays utilising human HUVEC cells and mouse retinal explants 
we found that the NA/EE-mixture directly impairs blood vessel pattern formation and nerve outgrowth. These 
findings demonstrate that the components of Primodos are potentially teratogenic, affecting the development of 
a wide range of zebrafish organ systems in vivo and further provides evidence that these components can affect 
the development of mammalian tissues in vitro.
Previous work in zebrafish embryos have studied the effects of prolonged EE or NA exposures (ie: continously 
from 0 hpf throughout embryonic development and up to adulthood). Such work has shown EE can disrupt fore-
brain neural patterning45,46 and cause defects including uninflated swimming bladder, body axis curvature and, 
pericardial and yolk sac oedemas47, cause embryonic malformations in resulting offspring48 and affect fertility49. 
In additon some progestins, including NA, have been shown to misregulate enzymes, like aromatase, essential 
for biosynthesis of estrogens in radial glial cells in the brain24. However, human embryos exposed to Primodos 
used as a pregnancy test would not be continously exposed to elevated hormone levels as done in these studies. 
Figure 6. NA/EE-mixture exposure in vivo and in vitro causes vessel formation anomalies The effect of NA/
EE-mixture on blood vessels was assessed by using zebrafish fli1:EGFP line and HUVEC culture. (A–F) In vivo 
growth of intersomitic blood vessels (highlighted by box in panel A) and patterning were analysed following 
treatment with either DMSO or NA/EE-mixture (NA 12.5 μg/mL and EE 25 ng/mL) for 6 or 24 hrs following 
treatment. (B) Ratio of intersomitic vessel length (ISV) to somite length 6 hrs and 24 hrs after treatment with 
DMSO (vehicle control) or NA/EE-mixture at 24 hpf. Statistical significance was analysed by Mann-Whitney 
test. (C,D) DMSO controls presented normal blood vessel growth and patterning when compared with 
untreated embryos (data not shown)41. (E,F) NA/EE-mixture treated embryos presented changes in growth 
and patterning of intersomitic vessels. (G–I) NA/EE-mixture disrupts the tube formation in HUVEC cultures 
in a dose-sensitive manner. (J,K) NA/EE-mixture reduces cell number and cell proliferation in a dose-sensitive 
manner in HUVEC cultures. Statistical significance was analysed using One-way ANOVA followed by Tukey’s 
test. Graphs represent mean ± SEM. **p < 0.01. Scale bar E: 100 µm; scale bar H: 500 µm. White arrowheads 
denote normal position and pattern of Intersomitic vessels. White asterisks indicate examples of misposition 
and mispatterning of vessels, including vessel fusions. Black asterisk denote avascular and poorly patterned 
areas of treated HUVEC cultures.
www.nature.com/scientificreports/
9ScIeNTIfIc REPORTS |  (2018) 8:2917  | DOI:10.1038/s41598-018-21318-9
We therefore exposed embryos to single doses of a combined NA/EE-mixture (in a ratio equivalent to that seen 
in Primodos) for 1–24 hr at 6, 24, 48 or 72 hpf, (a time period approximate to the developmental stage in human 
development that hormone pregnancy tests would likely be used) and demonstrated that this also caused dam-
age, although at higher concentrations (12.5 μg/mL NA + 25 ng/mL EE in our experiments versus 0.34 mg/L NA; 
14.8 ng/L EE and 1–20 ng/L EE in the prolonged exposure studies). Furthermore we have shown that the of NA/
EE-mixture induces damage rapidly, affecting movement of 24 hpf embryos within 1 hr of application and mor-
phological damage within 4 hrs. The difference in concentrations required to induce embryonic damage in this 
study compared to previous work45,46,48,49 likely reflects the shorter time course of drug application in our study. In 
Figure 7. In vivo and in vitro neuro-inhibitory effects of NA/EE-mixture exposure NA/EE-mixture effects 
on zebrafish nerve outgrowth and patterning. Embryos were treated at 24 hpf with either DMSO (A,C and E) 
or NA/EE-mixture (B,D and F) and fixed at 6 hours and 24 hours. Embryos incubated with DMSO present 
normal nerve outgrowth and patterning. Compared to DMSO controls, embryos treated with NA/EE-mixture 
presented fasciculation defects. White asterisk denotes end of yolk sac. White arrowheads denote position of 
major nerve tract in spinal cord; at 24 hr nerve tract is stunted and defasciculated in treated embryos, compare 
arrowheads in C and D. Nerves are missing in the head of treated embryos (F) compared with control embryos, 
grey arrowhead denotes axon projections (E). Direct effect of NA/EE-mixture on nerves was assessed through 
retinal explants culture exposed to DMSO and NA/EE-mixture over different concentrations; 0.05% DMSO 
(G), NA 3.125 μg/mL + EE 6.25 ng/mL (H), NA 6.25 μg/mL + EE 12.5 ng/mL (I) and NA 12.5 μg/mL + EE 25 ng/
mL (J) treatment. (K) Ratio of nerve length to body length is reduced in treated embryos at 6 hpf and 24 hpf as is 
the ratio of nerve outgrowth (L) in the head following treatment at 24 hpf. Statistical significance was analysed 
through Mann-Whitney test. (M) Neurite outgrowth in retinal explants was decreased significantly following 
NA/EE-mixture exposure at NA 6.25 μg/mL + EE 12.5 ng/mL (H and M) and NA 12.5 μg/mL + EE 25 ng/
mL (J and M). White arrow denotes an example of an axon projection. Statistical significance was analysed 
using Kruskal-Wallis test with Dunn’s post-hoc test. Graphs represent mean ± S.E.M. ns, p > 0.05; *p < 0.05; 
***p < 0.001. Scale bars: 100 µm.
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keeping with this idea, we have shown that the drug accumulates in embryos over time. Thus, prolonged exposure 
will likely result in higher concentrations within the embryo as development proceeds.
The dose we chose to investigate the action of the NA/EE-mixture upon embryonic development (12.5 μg/
mL NA + 25 ng/mL EE) was determined from carrying out a dose response analysis (Fig. 1). At the 24 hpf devel-
opmental timepoint lower doses had no effect, whilst higher doses caused severe damage or death. How does 
the dose used in our study compare with the doses used in humans? The peak of NA in human plasma aver-
ages 18.3 ng/mL, or 0.0183 μg/mL, when a 1 mg dose is taken50,51 and averages 26 ng/ml in human plasma with 
1–2 hours of administration with a 5 mg dose28. Considering that when used as a pregnancy test, the dose of 
Primodos taken was 10 mg, it is expected that the circulating NA would be higher. Moreover, given the nor-
mally elevated levels of progesterone and oestrogen during pregnancy, (from 10–54 ng/mL and 486–1615 pg/mL 
respectively)52–54 the use of a synthetic progesterone based hormone will result in a total higher concentration 
in pregnant versus non-pregnant women. We used Mass spectroscopy to measure the levels of NA within the 
zebrafish embryos and found that in just 6 hrs the concentration was 1 µg/embryo and the concentration peaked 
at 1.8 µg/embryo after 24 hr incubation. The doses we are using are higher than the plasmatic dose seen in humans 
after Primodos exposure. However, we do not know the receptor specificity or transport ability of these synthetic 
human hormones in zebrafish, which could be significantly different. Thus, it is difficult to extrapolate from our 
work what would be teratogenic dose in humans. Moreover, in human plasma the half-life of NA, a synthetic pro-
gestogen, is much longer (up to 9 hours)28,55 than endogenous progesterone (reportedly 5 mins)56. Even though 
the drug would then dilute throughout the blood plasma and likely be metabolised in the maternal liver, a study 
investigating NA/EE uptake in early human pregnancies showed levels of NA in the maternal blood plasma were 
elevated for up to 48 hrs after exposure, however, levels of NA/EE in the embryos were not described57. As there is 
little to no metabolic liver function in early embryogenesis58,59 it is possible that the drug concentration will accu-
mulate and build up to high levels in the human embryo over time, as we have observed in the zebrafish embryos.
The zebrafish possesses progesterone and oestrogen receptors and their expression patterns show potential 
roles in brain, ovary, testis, epidermis, head, trunk, hatching gland and pectoral fin buds60–62; tissues we have 
reported damage to following treatment with NA/EE. Oestradiol has also been shown to be involved with cardiac 
and liver development and also in embryonic heart rate regulation, changes to which could result in embryonic 
growth problems63,64. As well as this, progesterone signalling has been detected in the developing pancreas, cen-
tral nervous system, muscle, and pectoral fin buds65. This highlights the multiple embryonic tissues that the sex 
steroids can potentially influence. Whether this is via a direct, receptor mediated interaction or paracrine mech-
anisms remains unclear66.
Oestradiol also is involved with vitellogenin production in embryos which in turn goes on to form part of the 
yolk sac, a source of nutrients for the developing embryo67. If development of the yolk sac is abnormal, this may 
infringe upon nutrient supply to the embryo and may lead to additional congenital abnormalities. We see yolk 
sac changes as well as damaged tissues and changes in cell death and proliferation following exposure to NA/
EE-mixture. Progesterone also is known to be metabolised into corticosteroids such as cortisol by the foetal kid-
ney and adrenal gland68, which if found at high levels has teratogenic effecst in zebrafish69,70, and mammals such 
as sheep71. This raises the possibility that exogenous progesterone, and synthetic forms like NA, might metabolise 
into these teratogenic compounds, and thus cause developmental defects within the embryos.
We have shown the NA/EE-mixture has effects on cell death and cell proliferation in the zebrafish embryo and 
which could explain the reduced length and some of the tissue damage. We also show nerve damage which could 
explain the reduced embryo movement and possibly reduced embryonic length. Work in mouse and chicken 
embryos indicate loss of nerves in developing limbs can cause reduced outgrowth of the limb as a whole but 
not patterning defects/damage such as loss of specific bony elements72. This indicates nerve inhibition is more 
likely to exacerbate damage already caused by some other factor. We also demonstrate vascular changes in vivo 
in zebrafish embryos and also in vitro in HUVEC assays. Several known teratogens including thalidomide and 
valproate37,38 as well as anticancer antiangiogenic drugs34 are thought to cause embryonic damage through vessel 
inhibition. However precisely how loss of vessels results in embryonic damage remains unclear and further work 
is needed. Recent work has shown that progesterone and oestrogen regulates expression of vascular regulators 
including VEGF and angiopoietin in human73 and in primate endometrium66. Taken altogether, this suggests that 
the NA/EE-mixture can induce embryological defects through a range of mechanisms including, impaired nerve 
growth and angiogenesis, elevated cell death and impaired cell proliferation.
The range of damage seen in alleged victims of Primodos exposure has not been fully documented but includes 
damage in the extremities of the body including fingers and face, ears and CNS/brain6,7,11,13,14,74,75. We have found 
that the range of defects induced by the NA/EE-mixture depends on the stage of development when the embryo is 
exposed to the drug (Fig. 2). Exposure to very early stage embryos (6 hpf) causes much more severe damage than 
seen following exposure to late embryonic stages (72 pf; Fig. 2). The Primodos pregnancy test would have been 
taken over a large range of time in embryogenesis; women intending to become pregnant would likely have taken 
the test shortly after the first missed period, whilst women not expecting to be pregnant may wait longer. The 
time point at which the pregnancy test was taken would determine which developmental process has the most 
potential to be affected and thus result in a wide variety of potential defects, as seen in alleged Primodos survivors.
It is, of course, difficult and dangerous to directly compare drug action/s between species. Nevertheless, our 
data demonstrates accumulation of the drug in the embryo, which does not decrease for some time, and leads 
to rapid embryonic damage. From other animal models of drug-induced teratogenesis, for example thalidomide 
exposure, higher doses, than used in humans, are required to reciprocate the damage seen in humans due to dif-
ferences in applications, uptake and metabolism37,76–78. We have used a NA/EE-mixture composed of synthetic 
human progestogen and oestrogen compounds, but whether the zebrafish progesterone and oestrogen receptors 
bind these compounds with a similar affinity to human progesterone and oestrogen receptors is unclear, and 
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this might contribute to why high doses of the NA/EE-mixture were needed to see zebrafish embryonic damage. 
Clearly more work is required in mammalian species to confirm our findings.
In summary, we have shown that a NA/EE-mixture causes a range of damage to zebrafish embryos in a dose 
and time sensitive response to the NA/EE-mixture, which can accumulate in the embryo. The effects on the 
embryo are rapid, demonstrating that a short elevation in concentration is enough to induce damage. The con-
centration we have used is higher than human plasma concentrations of NA. However, given differences in drug 
application, absorption, metabolism and possibly species differences in sensitivity of receptors, caution must be 
applied when extrapolating drug concentrations across species. Moreover, as we have demonstrated NA accumu-
lates in the zebrafish embryo this may also occur in mammalian embryos and result in increased intraembryonic 
concentrations and, consequently, damage.
Taken altogether this work underlines the need for further, detailed research in mammalian species to deter-
mine the actions of the components of Primodos. Our studies in the zebrafish embryo has provided a starting 
point in understanding drug/compound action and determining the potential action of a drug/compound. This 
provides the basis and reasoning for further and more detailed studies in mammalian species to understand the 
full impact on mammalian embryos and the molecular pathways affected.
Materials and Methods
Compounds. Primodos (which is no longer available) was made up of 10 mg Norethisterone acetate (NA) 
and 0.02 mg Ethinyl estradiol (EE). Norethisterone acetate (NA; Sigma Aldrich) and Ethinyl Estradiol (EE; Sigma 
Aldrich) were dissolved in DMSO (Sigma-Aldrich) at stock concentrations of 25 mg/mL and 1 mg/mL, respec-
tively. The stock solutions were dissolved in distilled water to reach the final, working concentrations which were 
applied at a ratio between NA and EE equivalent to the dose given to women (500:1).
Zebrafish embryology and drug treatment. Adult zebrafish were bred and maintained as described 
previously35,41. Embryos collected from the tanks were kept in water to reach the desired developmental stage 
for drug treatment. Embryo stage is given in hours post fertilisation (hpf). Wildtype (WT) zebrafish embryos 
at 24 hpf, 48 hpf and 72 hpf were exposed to mixtures of NA/EE (in ratios equivalent to Primodos) under dif-
ferent concentrations or DMSO only (0.2%). Drug testing and analysis were carried out as described previ-
ously30,32,34,35,41. Briefly, embryos were hand dechorionated and exposed to the drugs or DMSO. For phenotypical 
analyses, embryos were fixed in 4% Paraformadehyde (Sigma-Aldrich) in 1x PBS at 96 hpf and for gene expression 
analyses, cell death and immunohistochemistry, embryos were fixed in 4% paraformaldehyde at 6 hr and 24 hr 
following treatment.
fli1:EGFP zebrafish embryos (obtained from the Zebrafish International Resource Center) were used to ana-
lyse the effects of the NA/EE mixtures on blood vessel growth using previously published protocols30,32,34,35,40,41. 
All animal research was licensed, approved and carried out following guidelines issued by the UK Home Office 
and University of Aberdeen Ethics Review Committee.
Whole-Mount immunohistochemistry. Whole-mount antibody staining was carried out as described 
previously41 with minor modifications: embryos at 48 hpf or older underwent bleaching (KOH Peroxidase) for 
20 minutes (48 hpf) or 30 minutes (72 hpf) and permeabilisation was performed with either ice-cold Acetone 
(Sigma-Aldrich) for 8 minutes at −20 °C for embryos up to stage 24 hpf or Collagenase A solution for 35 minutes 
(48 hpf) or 45 minutes (72 hpf). To label the nerves and proliferating cells, embryos were stained with 3A10 anti-
body (1:250; Developmental Studies Hybridoma Bank) or anti-Phosphohistone H3 antibody (1:150; Millipore 
06–570) respectively.
Cell death analyses. Cell death analyses were performed using the In Situ Cell Death Detection Kit 
(TUNEL-Roche) as described previously79. Briefly, tissues were fixed overnight in 4% PFA and washed in PBS 
for 5 minutes. Embryos were dehydrated in serial washes of ethanol and permeabilised with ice cold acetone for 
10 minutes at −20 °C. Embryos were rinsed in PBS and washed again in PBS for 30 minutes. Embryos underwent 
a second permeabilisation with 0.1% Triton, 0.1% Sodium citrate in PBS for 15 minutes and rinsed twice for 
5 minutes each in PBS. Embryos were incubated a mixture of 450 μL of solution 1 (TUNEL kit) and 50 μL of solu-
tion 2 (TUNEL kit for 60 minutes at 37 °C, rinsed 3 times in PBS for 10 minutes each and stored in PBS.
Cell culture. HUVEC cells (Lonza #C2517) were cultured in endothelial cell medium in 96 well tissue culture 
plates or with use of a HUVEC angiogenesis kit for vascular tube formation as described previously38. Cells were 
exposed to three concentrations of NA/EE mixture or 0.02% DMSO as a control. The cells were incubated for 
18 hr at 37 °C, fixed in 4% PFA for 1 hour, stained with antibodies for Phosphohistone H3 (Millipore; 1:500) and 
mounted in Vectashield with DAPI (Vector Laboratories).
Retinal explant cultures. Experiments were performed using wild-type E14.5 C57BL/6 J mouse embryos 
from an in-house breeding colony. Retinal explants were prepared and analysed as described previously32,43. 
Results are the mean (±SEM) from two independent experiments for each condition.
Imaging and analyses. Imaging of embryos was performed using a Nikon SMZ1500 fluorescent stereom-
icroscope with a Nikon DS-5 digital camera or using a Zeiss Axiophot epifluorescent microscope with a Nikon 
DXM1200 camera. Images of HUVEC cultures were captured on a Nikon Eclipse TS100 microscope fitted with 
a DS-Fi1c camera with NIS-Elements D software and images of retinal explants were captured using a Nikon 
SMZ1500 microscope and DXM1200 camera with ACT-1 software. Data were analysed using Adobe Photoshop 
and Image J. Quantification of embryonic intersomitic vessel outgrowth and nerve outgrowth between treated 
and control conditions was measured using Image J. To take into account differences in embryo length results are 
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displayed as a ratio between nerve or vessel length to body or somite length respectively. Statistical analyses were 
conducted using Prism 5.0 (GraphPad Software, La Jolla, CA) or SPSS 20.0 (SPSS Inc., Chicago, USA). Statistical 
significance was assessed using two-tailed unpaired Student’s t-test, Mann-Whitney U-test, One-way ANOVA 
or Kruskal-Wallis test followed by Tukey’s or Dunn’s test respectively. Error bars represent standard error of the 
mean.
Video imaging and analyses. Zebrafish embryos were placed in wells of a 24-well plate from 24 hpf 
and treated with DMSO or NA/EE-mixture for 1–24 hr. No more than 5 embryos were placed in one well. The 
embryos were imaged using time-lapse recording on NIS-elements D software, captured at one image per 10 m/s. 
Each embryo was analysed individually for the number of movements in 2 minutes, then the average number of 
movements per embryo per minute was calculated. A Mann Whitney test was used for statistical analysis.
Determination of Norethisterone acetate (NA) concentration in zebrafish embryos by 
HPLC-MS/MS. Norethisterone acetate (NA) levels were determined using a rapid LC-MS/MS assay. NA was 
dissolved in water at a concentration of 1 mg/mL and stored in aliquots at −20 °C. Quality control samples were 
prepared in water/methanol (50/50) at 10, 85 and 175 ng/mL NA and stored at −70 °C. Daily, NA was diluted in 
water/methanol (50/50) to give calibration standards in the range 6.25–200 ng/mL.
Embryos were exposed to the NA/EE-mixture for the appropriate time period and then rinsed in 10 ml water 
three times to remove excess solution. Embryos were stored individually in 100 µl of water and frozen for anal-
ysis. Individual embryos in 100 µL of water were homogenised by sonication and the resulting solution diluted 
1:10 with water/methanol (50/50) and following centrifugation at 14800 rpm at 4 °C, 5 µL was injected onto the 
chromatograph. Chromatography was performed on a Thermo Surveyor (Thermo Scientific, UK) system using a 
150 × 2.1 mm ACE 3 µ C18 column (Hichrom, UK) maintained at 50 °C. NA was resolved using isocratic elution 
with a mobile phase composition of 15% water/85% methanol (both containing 0.1% formic acid). The flow rate 
was 200 µL/min and the samples were maintained at 4 °C in the autosampler. NA eluted at 3.34 minutes and the 
total run time was 3.8 minutes.
A Thermo TSQ Quantum triple quadrupole mass spectrometer was used in positive electrospray ionisation 
mode for the detection of NA. Quantification was performed using multiple reaction monitoring (MRM) scan 
mode using the following transitions: m/z 341.2–91.1 at collision energy 35 V and m/z 341.2–109.1 at collision 
energy 26 V. Flow injection analysis was used to optimise the MS/MS conditions as follows: spray voltage 4000 V, 
sheath gas pressure 20, auxiliary gas pressure 35, capillary temperature 375 °C, skimmer offset −14V and collision 
pressure 2.0 mTorr. Instrument control and peak integration and quantification were performed using Thermo 
Xcalibur software (v. 3.0). Weighted least squares linear regression with a weighting factor of 1/X2 was used to 
quantify NESA concentrations in unknown samples by comparison of peak areas with those obtained from a 
multi-level calibration standard curve. The LLOQ for the assay was 1 ng/mL and the intra and inter-assay varia-
tions were determined to be <3% and <6% respectively.
Ethical approval. All experimental protocols and procedures were approved by the University of Aberdeen 
Ethical Review Panel and is fully licensed by the UK Home Office.
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